Highlighting measurable progress across environmental, social and governance dimensions, the report demonstrates how sustainability is embedded across Kayentis’ operations, governance and innovation, supporting more transparent, ethical and efficient clinical trials
Meylan, France – July 9, 2026 — Kayentis, a global leader in eCOA and decentralized clinical trial solutions, today announced the publication of its first Environmental, Social and Governance (ESG) report, marking a major milestone in its journey to embed sustainability and responsibility at the heart of clinical research.
Covering the fiscal year April 2025 to March 2026, this inaugural report provides a transparent, data-driven view of Kayentis’ ESG strategy, progress, and priorities, reflecting a long-standing commitment to responsible business practices and continuous improvement.
Recognized progress
People-centric culture supporting performance and innovation
Kayentis continues to invest heavily in employee experience, with strong engagement and satisfaction levels:
- 95% of employees report good or excellent well-being at work
- 96% are satisfied with their work-life balance
- 98% are satisfied with relationships within their teams
The company also demonstrates a strong commitment to diversity and inclusion, with 23 nationalities represented and a 99/100 Gender Equality Index for five consecutive years.
Concrete environmental actions with clear ambitions
Kayentis has set a clear objective to reduce its carbon footprint by 30% per million euros of revenue by 2030, supported by enhanced measurement and supplier engagement.
A long-term journey of transparency and improvement
Kayentis will publish its ESG report annually as part of its commitment to transparency and continuous progress.
Guillaume Juge
CEO at Kayentis
“Sustainability is a long-term journey. We are committed to moving forward with humility, determination, and a strong sense of responsibility, together with our stakeholders.”
About Kayentis
Kayentis is a global leader in electronic Clinical Outcome Assessment (eCOA) and Decentralized Clinical Trial solutions. For over 20 years, it has partnered with pharma, biotechs and CROs in streamlining data collection and enhancing data quality across clinical trials worldwide. To date, Kayentis has supported more than 400 clinical trials in over 90 countries. Its expertise spans all clinical phases (I–IV) and more than 200 indications across 20+ therapeutic areas, delivering a comprehensive, science-driven and patient-centric suite of services. Operating across the US, Europe and Asia, Kayentis is recognized for its commitment to quality, innovation and operational excellence. With a 95.9% client recommendation rate in 2026, consistently rating above 90% over the past five years, Kayentis continuously adapts its solutions to meet the growing complexity of clinical trials and to improve outcomes for sponsors, sites and patients alike.
